2272

百力特®點眼懸浮液
Poly-Pred® Liquifilm® Ophthalmic Suspension

衛署藥輸字第018646號

主成份：

每毫升含

Prednisolone acetate.....5mg

Neomycin Sulfate

(equivalent to 3.5mg neomycin base).....5mg

Polymyxin B Sulfate.....10,000 units

Liquifilm (Polyvinyl alcohol).....14mg

適應症：

類固醇局部抗發炎製劑暨抗感染製劑。

說明：

Poly-pred可用於治療眼睛疾患，需要抗發炎治療以及若合併有對Neomycin或Polymyxin有感受性的菌種所導致的併發性感染如：

結合膜炎、瞼結合膜炎、鞏膜炎、非疱疹性角膜炎、淚囊炎、術後預防感染、異物侵入(包括化學及熱灼傷)所引起之炎症。

禁忌：

急性單純性疱疹(樹枝狀角膜炎)、牛痘、水痘、眼結核及由黴菌、病毒感染之眼疾、或任何對主成份過敏者。

警語：

1. 類固醇製劑的使用可能會遮蔽或加重微生物感染之眼疾。
2. 曾有報告在長期使用局部類固醇後，會發生後囊下白內障或眼內壓上升，應經常檢查眼內壓。
3. 有些疾病及長時間投與局部類固醇會引起角膜變薄，使用局部類固醇製劑時，有可能造成角膜穿孔。
4. 長時間使用局部類固醇有可能使遮蔽性微生物過度滋長，當因此引起二次感染時，則停止投藥，並給與適當處置。
5. 長時間使用後，若慢性眼部發炎現象仍在，則應考慮黴菌感染的可能性。
6. 對曾有單純性疱疹病史的病患投與類固醇製劑應特別小心。
7. 在眼部急性化膿性狀況下，類固醇有可能會遮蔽或加重感染的情形。
8. Neomycin Sulfate有引起皮膚敏感之潛在可能性，但確實發生率不明。

注意：

尚未確立對孕婦局部投與類固醇的安全性，所以在懷孕期間不宜長時間或大量投與類固醇，對兒童的安全性及有效性未建立。

用法、用量：

治療眼球：每3-4小時1滴或需要時可增加投與次數。

治療眼瞼：每3-4小時1滴，並閉上眼睛輕揉眼瞼。

治療眼旁周圍：當發炎現象同時出現在眼睛及眼旁周圍皮膚時，藥水可直接分佈到發炎部位，再讓其自然乾即可。

包裝：

5ml塑膠點眼滴瓶。

儲存在15℃-25℃間，避免冷凍，避免被孩童拿到。

本藥須由醫師處方使用。

使用前請先搖晃均勻。

製造廠：Allergan Pharmaceuticals Ireland

廠　址：Castlebar Road, Westport County, Mayo, Ireland.

藥　商：香港商愛力根有限公司台灣分公司

地　址：台北市羅斯福路二段102號9樓

電　話：(02)2366-9888

72049UT10X

INSET STANDARDIZED,
4" X 10"
0284301

- Part number: 72049UT10X
- Drawing number: 0284301
- V-code: 2272
- Artwork is actual size
- Drop template and notes before processing

POLY-PRED™

(prednisolone acetate - neomycin sulfate - polymyxin B sulfate)

LIQUIFILM™

sterile ophthalmic suspension



ALLERGAN



DESCRIPTION

Each mL contains: prednisolone acetate 5 mg, neomycin sulfate (equivalent to 3.5 mg neomycin base) 5 mg, polymyxin B sulfate 10,000 units with: LIQUIFILM™ (polyvinyl alcohol) 14 mg, thimerosal 0.01 mg, polysorbate 80, propylene glycol, sodium acetate and purified water.

INDICATIONS

POLY-PRED™ is indicated for the treatment of eye disorders requiring anti-inflammatory therapy and where complications by infection caused by bacteria sensitive to neomycin and/or polymyxin are present or a potential hazard, such as: nonpurulent conjunctivitis and blepharitis, scleritis, nonherpetic keratitis, dacryocystitis, and for prophylactic therapy following eye surgery, foreign body removal, chemical or thermal burns, abrasions, lacerations or other ocular trauma.

CONTRAINDICATIONS

Acute herpes simplex (dendritic keratitis), vaccinia, varicella and most other viral diseases of the cornea and conjunctiva, ocular tuberculosis, fungal diseases of the eye, and in those individuals who have shown hypersensitivity to any of the drug's ingredients.

WARNINGS

In diseases due to microorganisms, infection may be masked, enhanced or activated by the steroid. Extended use of topical steroid therapy may result in increased intraocular pressure resulting in glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation. It is advisable that intraocular pressure be checked frequently. Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation. Prolonged use may result in overgrowth of non-susceptible organisms. If superinfection occurs, discontinue use of this drug and institute appropriate therapy. When signs of chronic ocular inflammation persist following prolonged corticosteroid dosing, the possibility of fungal infections of the cornea should be considered. Wound healing may be delayed by the use of topical corticosteroids.

Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution.

In acute purulent conditions of the eye, corticosteroids may mask infection or enhance existing infection.

There exists a potential for neomycin sulfate to cause cutaneous sensitization. The exact incidence of this reaction is unknown.

PRECAUTIONS

The safety of the use of topical steroids during pregnancy has not been established. Safety and effectiveness in children have not been evaluated.

DOSAGE AND ADMINISTRATION

TO TREAT THE EYE: 1 drop every 3 to 4 hours, or more frequently as required. TO TREAT THE LIDS: Instill 1 drop in the eye every 3 to 4 hours, close the eye and rub the excess on the lids and lid margins. TO TREAT THE SURROUNDING SKIN AREAS: Where the eye or lid inflammation co-exists with surrounding skin involvement, drops may be spread liberally on the area and allowed to dry.

HOW SUPPLIED

5 mL plastic dropper bottles.

Note: Store between 15° - 25°C; protect from freezing. Store upright. On prescription only. Keep out of the reach of children. **Shake well before use.**

ALLERGAN

Allergan Pharmaceuticals Ireland
Castlebar Road, Westport, County Mayo, Ireland.

72059AS10X

INSERT, TYPE B2,
PENCIL FOLD,
114MM X 220MM,
FOLDED TO 114MM X 23MM
0106501

- Part number: 72059AS10X
- Drawing number: 0106501
- Artwork is actual size
- Drop template and notes before processing